Lexeo Therapeutics Inc (LXEO) FinancialsLXEOLexeo Therapeutics Inc

Evaluating the bottom line, Lexeo Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -46.76%, provide a clear picture of how effectively LXEO converts its operational activities into shareholder value.

In the context of the broader market, LXEO competes directly with industry leaders such as LRMR and CABA. With a market capitalization of $265.02M, it holds a significant position in the sector. When comparing efficiency, LXEO's gross margin of N/A stands against LRMR's N/A and CABA's N/A. Such benchmarking helps identify whether Lexeo Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Lexeo has reported a consistent pattern of losses, with a net income loss of $25.9 million in Q4 2024 and a gross profit of $0. The current ratio is strong at 14.16, indicating good liquidity, but the overall financial health is concerning due to ongoing losses.